Clinical trials: Multiple Myeloma (MM)
Multiple Myeloma (MM)
Benefits of a 6-month, Individualized, Hybrid, "Real-life" Adapted Physical Activity Program on the Quality of Life of Patients Treated for Multiple Myeloma
The goal of this clinical trial is to evaluate the effect of a long-term, individualized, hybrid adapted physical activity program on the quality of life of patients with multiple myeloma.
- Trial name
- BAPAMM (NCT07547007)
- Testing
- Adapted physical activity
- Where
- 2 sites in France
- Volunteers
- 86 people
- Sponsor
- Centre Hospitalier Metropole Savoie
Multiple Myeloma (MM)
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
This is a single-arm, open-label, single-center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of QI-019B in patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT07539233
- Testing
- QI-019B Injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma (MM)
BR101 in Patients With Relapsed/Refractory Multiple Myeloma
This study is an open-label, single-arm, dose-escalation and dose-expansion clinical trial designed to evaluate the maximum tolerated dose, safety, pharmacokinetic profile following administration of BR101 injection, and…
- Trial name
- NCT07537049
- Testing
- BR101 injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Multiple Myeloma (MM)
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
This is a multicenter, open-label phase II study with 2 parallel cohorts for frail patients with newly diagnosed multiple myeloma treated with daratumumab in combination with teclistamab and talquetamab.
- Trial name
- NCT07107529
- Testing
- Teclistamab, Talquetamab, Daratumumab
- Where
- 29 sites in Italy, Netherlands and 2 more
- Volunteers
- 150 people
- Sponsor
- European Myeloma Network B.V.
MULTIPLE MYELOMA (MM)
Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
This study will evaluate the safety and the efficacy of carfilzomib combined with cyclophosphamide and dexamethasone (CCyd) or lenalidomide and dexamethasone (CRd) followed by autologous transplantation ASCT or 12 cycles of…
- Trial name
- FORTE (NCT02203643)
- Testing
- Carfilzomib, Cyclophosphamide, Lenalidomide
- Where
- Italy
- Volunteers
- 477 people
- Sponsor
- Mario Boccadoro
Relapsed/Refractory Multiple Myeloma (MM)
Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma.
- Trial name
- CART-BCMA (NCT07458659)
- Testing
- Chimeric Antigen Receptor T Cells (CAR-T)
- Where
- Thailand
- Volunteers
- 3 people
- Sponsor
- Chulalongkorn University
Multiple Myeloma (MM)
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
The purpose of this study is to see if researchers could get the same good results with less toxicity by using this new approach.
- Trial name
- NCT01919086
- Testing
- Bortezomib, Dexamethasone, Lenalidomide
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma (MM)
CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)
Multiple myeloma patients can be treated with cell therapy, which uses some of their own modified white blood cells (T lymphocytes) to target a protein (BCMA, or B-cell maturation antigen) found on the surface of the myeloma…
- Trial name
- CART I5M (NCT07342179)
- Testing
- Additional Bone Marrow cells and blood sampling
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Poitiers University Hospital
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Multiple Myeloma (MM)
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory multiple myeloma.
- Trial name
- LB2505-0001 (NCT07399444)
- Testing
- LVIVO-TaVec400 product
- Where
- 6 sites in China
- Volunteers
- 38 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma (MM)
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free…
- Trial name
- NCT07297329
- Testing
- SCTC21C, Bortezomib, Lenalidomide
- Where
- China
- Volunteers
- 292 people
- Sponsor
- Sinocelltech Ltd.
Multiple Myeloma (MM)
Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma
This study intends to employ 68Ga-NOTA-BCMA nanobody PET/CT imaging in patients with multiple myeloma to evaluate the feasibility of this technique for myeloma assessment, analyze the correlation between 68Ga-NOTA-BCMA nanobody…
- Trial name
- NCT07353554
- Testing
- 68Ga-BCMA nanobody PET/CT, 18F-FDG PET/CT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, CART Therapy
Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)
CAR-T cell or bispecific antibody therapies are a new treatment option for adult patients with aggressive forms of lymphoma or so-called plasma cell diseases ('multiple myeloma', 'plasma cell myeloma') that could not be cured…
- Conditions
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, CART Therapy, Bispecific Antibody, Geriatric Hematology
- Trial name
- GA-ACT (NCT07309497)
- Testing
- pragmatic geriatric assessment
- Where
- 2 sites in Switzerland
- Volunteers
- 208 people
- Sponsor
- University of Zurich
Relapsed/Refractory Multiple Myeloma(MM)
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed/refractory multiple…
- Trial name
- NCT07100067
- Testing
- LCAR- F33S cells intravenous infusion
- Where
- 4 sites in China
- Volunteers
- 35 people
- Sponsor
- Nanjing Legend Biotech Co.
Lymphoma, Leukemia
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Venous Thromboembolic Disease
- Trial name
- HEM-DOAC (NCT07270263)
- Testing
- Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Gdansk
Leukaemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
With the rapid advancement of biopharmaceutical technology, clinical trials have become the crucial bridge connecting new drugs from the laboratory to clinical application.
- Conditions
- Leukaemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Lymphoma
- Trial name
- NCT07305337
- Testing
- Artificial Intelligence Health Education, Artificial health education
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Zhongnan Hospital
Multiple Myeloma (MM)
A Study of WVT078 in Patients With Multiple Myeloma (MM)
The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple…
- Trial name
- NCT04123418
- Testing
- WVT078, WHG626
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma (MM), Exercise
Effects of a Resistance Physical Exercise Program in Multiple Myeloma Patients
The goal of this clinical trial is to learn if physical exercise improves quality of life, frailty and mental health in patients with multiple myeloma. It will also learn about the safety and adherence of the program.
- Conditions
- Multiple Myeloma (MM), Exercise, Cancer
- Trial name
- NCT07253103
- Testing
- Supervised physical exercise, Home-based physical exercise program
- Volunteers
- 50 people
- Sponsor
- University of Salamanca
Relapsed/Refractory Multiple Myeloma(MM)
Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma
The purpose of this clinical trial is to learn if allogeneic cord blood-derived CAR-T cell drug works to treat Multiple Myeloma (MM) including Bone-related extramedullary (EMB) disease and extramedullary extraosseous disease(EME)…
- Trial name
- UCAR-T_MM-XA (NCT07139509)
- Testing
- allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Xi'an No.3 Hospital
Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML)
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
The purpose of the study was to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients with Non-Hodgkin lymphoma (NHL), Multiple Myeloma…
- Conditions
- Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
- Trial name
- NCT04702425
- Testing
- VOB560, MIK665
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals